Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
22
ACET Quote, Financials, Valuation and Earnings
Last price:
$0.50
Seasonality move
:
2.71%
Day range:
$0.46 - $0.51
52-week range:
$0.45 - $1.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.50x
P/B ratio:
0.69x
Volume:
6.1M
Avg. volume:
2.5M
1-year change:
-42.61%
Market cap:
$75.7M
Revenue:
--
EPS (TTM):
-$1.26
Analysts' Opinion
-
Consensus RatingAdicet Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.17, Adicet Bio, Inc. has an estimated upside of 1351.63% from its current price of $0.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $0.49.
Fair Value
-
According to the consensus of 7 analysts, Adicet Bio, Inc. has 1351.63% upside to fair value with a price target of $7.17 per share.
ACET vs. S&P 500
-
Over the past 5 trading days, Adicet Bio, Inc. has underperformed the S&P 500 by -1.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Adicet Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Adicet Bio, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Adicet Bio, Inc. reported revenues of --.
Earnings Growth
-
Adicet Bio, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Adicet Bio, Inc. reported earnings per share of -$0.29.
Enterprise value:
-11.9M
EV / Invested capital:
--
Price / LTM sales:
1.50x
EV / EBIT:
--
EV / Revenue:
-1.85x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$6.5M
Return On Assets:
-59.85%
Net Income Margin (TTM):
--
Return On Equity:
-71.7%
Return On Invested Capital:
-65%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$8.2M | -$6.5M | -$6.5M | -$1.6M | -$1.6M | |
| Operating Income | -$132.6M | -$128.4M | -$121M | -$33.2M | -$28M | |
| EBITDA | -$124.3M | -$121.9M | -$114.5M | -$31.6M | -$26.4M | |
| Diluted EPS | -$3.35 | -$1.70 | -$1.26 | -$0.34 | -$0.29 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $199M | $285.7M | $185.9M | $206.3M | $106.5M | |
| Total Assets | $257.2M | $354.3M | $233.3M | $246M | $140.5M | |
| Current Liabilities | $20M | $17.2M | $19.8M | $19.4M | $18.9M | |
| Total Liabilities | $40M | $36.6M | $38.6M | $34.4M | $31.3M | |
| Total Equity | $217.2M | $317.7M | $194.7M | $211.5M | $109.1M | |
| Total Debt | $20.5M | $19.3M | $18.7M | $14.9M | $12.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$89.1M | -$91.8M | -$98.4M | -$22M | -$22.3M | |
| Cash From Investing | -$10.8M | -$97.3M | $24.8M | -$96.6M | $16.8M | |
| Cash From Financing | $463K | $111.2M | $150K | -- | -$150K | |
| Free Cash Flow | -$99.9M | -$92.8M | -$100.4M | -$22.4M | -$22.5M | |
ACET
Sector
Market Cap
$75.7M
$27.9M
Price % of 52-Week High
44.48%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
0.47%
-1.49%
1-Year Price Total Return
-42.61%
-16.66%
Beta (5-Year)
1.610
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.49
200-day SMA
Sell
Level
$0.71
Bollinger Bands (100)
Sell
Level
0.59 - 0.87
Chaikin Money Flow
Sell
Level
-93.7M
20-day SMA
Sell
Level
$0.54
Relative Strength Index (RSI14)
Sell
Level
35.85
ADX Line
Sell
Level
25.84
Williams %R
Neutral
Level
-78.2946
50-day SMA
Sell
Level
$0.69
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
77.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.7837)
Sell
CA Score
(Annual)
Level (-1.6212)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.5852)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, ACET has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACET average analyst price target in the past 3 months is $7.17.
-
Where Will Adicet Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Adicet Bio, Inc. share price will rise to $7.17 per share over the next 12 months.
-
What Do Analysts Say About Adicet Bio, Inc.?
Analysts are divided on their view about Adicet Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Adicet Bio, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Adicet Bio, Inc.'s Price Target?
The price target for Adicet Bio, Inc. over the next 1-year time period is forecast to be $7.17 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACET A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Adicet Bio, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACET?
You can purchase shares of Adicet Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Adicet Bio, Inc. shares.
-
What Is The Adicet Bio, Inc. Share Price Today?
Adicet Bio, Inc. was last trading at $0.50 per share. This represents the most recent stock quote for Adicet Bio, Inc.. Yesterday, Adicet Bio, Inc. closed at $0.49 per share.
-
How To Buy Adicet Bio, Inc. Stock Online?
In order to purchase Adicet Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ACET Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ACET
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
0.69x
1.81x
Price / LTM sales
1.50x
1.58x
Growth Metrics
ACET
Sector
Revenue growth
--
4.62%
Earnings growth
12.13%
10.5%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$0.18
-$0.21
Profitability
ACET
Sector
Profitability FY 2024
-$6.5M
$3.6M
Return on invested capital
-65%
-31.87%
Return on assets
-59.85%
-28.18%
Return on equity
-71.7%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
4
Balance Sheet
ACET
Sector
Total cash
$103.1M
$26.4M
Short term investments
$119.8M
$25.7M
Total assets
$220.2M
$76.9M
Long term debt
$12.6M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
